Page 2 - Novartis

Novartis buys Aspen's Japanese generic unit for up to 400 million euros

Aspen Pharmacare has abandoned its dividend this year and is selling assets to pay down debt after levels moved close to breaching debt covenants

Price of key diabetes drug may crash as Novartis risks losing patent

A look at the top 10 brands of Novartis in India shows that mature brands like Voveran and Calcium Sandoz are clocking low single-digit growth

Here's why Novartis CEO thinks FDA process could have been handled better

Novartis has said that it learned of the data manipulation on March 14 and alerted the US Food and Drug Administration

Novartis replaces top scientists at Avexis unit over drug data manipulation

The Swiss drugmaker said last week that it was in the process of 'exiting' the Avexis scientists responsible for the manipulation of data on gene therapy Zolgensma

Novartis' $2-mn therapy for rare disorder is world's most expensive drug

Novartis executives defended the price, saying that a one-time treatment is more valuable than expensive long-term treatments

Novartis CEO Narasimhan's $50 billion of deals was just the first act

With plans to spend more than $10 billion a year on acquisitions, Big Pharma's youngest boss is hunting for partnerships to develop groundbreaking gene therapies

Novartis to acquire US-based cancer drugmaker Endocyte for $2.1 billion

Novartis earlier this year announced the purchase of rare-disease drugmaker AveXis Inc. for $8.7 billion

Novartis India Vice Chairman and Managing Director Jawed Zia resigns

Novartis India today said its Vice Chairman and Managing Director Jawed Zia has decided to step down from the post. "Jawed Zia, Vice Chairman & Managing Director, Novartis India Limited has informed the Board of Directors of his decision to step down from the office of Vice Chairman and Managing Director at the close of business hours on May 31, 2018," the company said in a BSE filing. The board, the filing said, has requested the nomination and remuneration committee to identify and recommend a suitable successor for the role of Vice Chairman and Managing Director of the company. In India, the pharmaceutical business of Novartis India Ltd is focused on bone and pain, calcium portfolio, gynaecology and neuroscience and the generic business is focused on gynaecology, anti-TB and anti-infectives.

Novartis CEO Narasimhan sets up new leadership after four top exits

Narasimhan, who took over as CEO in February, is emphasising the role of digital technology in helping Novartis come up with winning new therapies

Novartis' $475,000 cancer breakthrough heralds new era of cures

Novartis's arrangement to pay only if patients respond to the drug as a huge breakthrough

Novartis to pay $665 mn for US blood disease drugmaker

The Swiss drugmaker expands its pipeline of medicines to combat blood diseases